Burgess B. Freeman

The paper introduces SINBA, a computational framework that identifies synergistic, brain-penetrant drug combinations for high-risk medulloblastoma, validating several candidates in preclinical models.

This study shows that targeting RBM39 with indisulam promotes natural killer cell activity and eradicates neuroblastoma regardless of cellular state plasticity.

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

This paper establishes a diverse collection of preclinical models for pediatric solid tumors and demonstrates their utility in precision medicine trials and drug testing.